Licensing opportunities and technologies are sourced from both the UK’s Medical Research Council and from our drug discovery and diagnostics labs.

MRC Technology is responsible for the technology transfer of patented and protected technologies from the MRC, MRC Technology, and other academic and charitable organisations.

We have technologies available in; Bioinformatics and Diagnostics, Biologics, Cancer, Cardiovascular and Respiratory system, Drug discovery/Drug delivery, Genetics/Genomics/Epigenetics, Infectious diseases/Immunology/Vaccines, Metabolic diseases, Neurobiology, Research tools/Enabling technologies, Software & devices.

If you can’t find what you’re looking for please contact us.

Below is a list of our current therapeutics licensing opportunities.

Alternatively, to view our drug discovery pipeline click here

  • Next generation cell penetrating peptides as a drug delivery system

    Cell penetrating peptides with demonstrated efficacy in transporting biological molecules into cells and improving disease outcome in vivo

  • ALK

    Antibody-drug conjugate discovery project for cancer

  • ULK1

    The protein kinase ULK1 is a major regulator of autophagy, and blocking this molecule in cancer cells would reduce their capacity to cope with stress. We are screening for small molecule inhibitors of ULK1 as novel cancer therapeutics.

  • Netrin-1

    Netrin-1 is an axonal guidance factor and is an attractive therapeutic target for osteolytic diseases. We are developing a therapeutic antibody against netrin-1.

  • MNK

    MNK is a promising cancer target in a variety of tumour types. We have generated two novel series of small molecule MNK inhibitors that are active against both MNK1 and MNK2.

  • Enterovirus 71

    Enterovirus 71 (EV71) is one of the dominant causative agents of HFMD. We have developed a humanised monoclonal antibody that potently neutralises EV71.

  • Targeting cancer therapeutics with palladium-activated compounds

    Enables targeted delivery of well characterised and effective anti-cancer drugs such as 5-fluorouracil and floxuridine

  • Ang2 specific biotherapeutic

    Ang2 inhibitor as biotherapeutic for cancer, sepsis and variety of inflammatory disorders

  • HIVcon: a universal, clinically validated HIV-1 vaccine

    Addresses problem of enormous diversity of HIV-1

  • IL-17BR

    Therapeutic antibody against type 2 immune responses, including lung fibrosis, asthma and ulcerative colitis

  • A humanized, broadly neutralising therapeutic HCV antibody

    Good candidate for therapeutic use

  • Cardioprotection following heart attack

    Novel small molecule therapeutic for ischemia-reperfusion injury

  • Multiple sclerosis

    Small molecule inhibitor decreases progression of MS

  • Hormone dependent tumours

    Assay and peptides that could lead to new tumour suppressing therapies

  • Wound healing

    GMCSF and PGE synergistic combination for topical application or incorporation into dressings

  • Hormone dependent diseases

    Series of kisspeptin peptide antagonists for development as therapeutics

  • Parkinson’s disease; surgical technique

    Allows unambiguous identification of neural centres for deep brain stimulation treatments

  • GalR2

    Drug discovery project for novel pain therapeutics that target GalR2

  • Kir 7.1

    Post partum haemorrhage project looking for small molecule inhibitors of Kir7.1


    Migraine drug discovery project looking for TRESK activators

  • Small molecule TrkA-NGF inhibitors for pain

    TrkA is a drug discovery project for pain

  • TBK1

    TBK1 is a small molecule drug discovery project for inflammatory disease

  • IL16

    Humanised monoclonal antibody for immune-mediated diseases

Can't find a suitable opportunity?

Please register (below) for alerts on new opportunities or contact us to discuss your requirements.

Don't miss out

Please register now to ensure you receive details of new opportunities as they become available.

Please enter the code into the below box to prove you are human:


You could benefit from our resources and expertise

To discuss any of our current licences and find out about the research areas we are currently exploring please get in touch with our business development team.